Report Detail
Warts - Pipeline Review, H2 2019
- RnM3784275 |
- 26 September, 2019 |
- Global |
- 105 Pages |
- Global Markets Direct |
- Pharma & Healthcare
Warts - Pipeline Review, H2 2019
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H2 2019, provides an overview of the Warts (Infectious Disease) pipeline landscape.
Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Warts - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 12, 5, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 2 molecules, respectively.
Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Warts - Overview
Warts - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Warts - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Warts - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Cutanea Life Sciences Inc
Cytovation AS
G&E Corp
Genetic Immunity Inc
Laboratories Ojer Pharma SL
Leo Pharma AS
Maruho Co Ltd
Nielsen Biosciences Inc
Novan Inc
Pfizer Inc
Phio Pharmaceuticals Corp
Tamir Biotechnology Inc
Verrica Pharmaceuticals Inc
Warts - Drug Profiles
(digoxin + furosemide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
854-A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Albicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Condyloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Human Papillomavirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CyPep-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FIT-039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
furosemide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus (9 valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus (9 valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [serotypes 6, 11] (bivalent, virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HupaDerm - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydrogen peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ingenol mebutate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omiganan pentahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pefcalcitol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranpirnase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RKP-00156 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Samcyprone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Warts - Dormant Projects
Warts - Discontinued Products
Warts - Product Development Milestones
Featured News & Press Releases
Jul 24, 2019: Novan’s drug substance demonstrates inhibition of HPV-18 virus production
Jun 27, 2019: Verrica Pharmaceuticals enrolls first patient in Phase 2 trial of VP-102 for the treatment of external genital warts
Jun 26, 2019: Verrica Pharmaceuticals achieves positive topline results in phase 2 clinical study of VP-102 in [atients with common warts
Mar 18, 2019: Cytovation initiates clinical development programme with CyPep-1, a first-in-class lytic agent for tumor immunotherapy
Feb 19, 2019: Aclaris Therapeutics to present scientific posters at the 77th Annual Meeting of the American Academy of Dermatology
Nov 01, 2018: Novan Publication Supports Women's Health Business Unit Initiative and Nitric Oxide's Potential Against HPV-Associated Diseases
Sep 24, 2018: Aclaris Therapeutics Announces First Patient Dosed in Phase 3 Studies Evaluating A-101 45% in Patients with Common Warts
Jul 19, 2018: Cassiopea announces top line positive proof of concept phase II results for CB-06-02 immune modulator in treating genital warts
May 18, 2018: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone for the Treatment of Common Warts
Apr 04, 2018: RXi Pharmaceuticals to Present on Samcyprone at the International Investigative Dermatology Conference
Mar 19, 2018: Aclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up of A-101 45% Topical Solution for Potential Treatment of Common Warts
Jan 08, 2018: Aclaris Therapeutics A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts
Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts
Sep 06, 2017: RXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts
Jun 29, 2017: Aclaris Therapeutics Initiates Phase 2b Clinical Trials of A-101 for Topical Treatment of Common Warts
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Summary:
Get latest Market Research Reports on Warts. Industry analysis & Market Report on Warts is a syndicated market report, published as Warts - Pipeline Review, H2 2019. It is complete Research Study and Industry Analysis of Warts market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
